Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 28enzalutamide 27Specimen Handling 21apalutamide 18Androgen Antagonists 16Prednisone 15Abiraterone Acetate 15Radiosurgery 13abiraterone 11Radiotherapy 10Docetaxel 10Biopsy 9darolutamide 8Pluvicto 8Nivolumab 8niraparib 6cabazitaxel 6Surveys and Questionnaires 6Radiation 6Lutetium-177 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6gallium 68 PSMA-11 5bicalutamide 5Radiotherapy, Intensity-Modulated 5Lutetium 5Gonadotropin-Releasing Hormone 5radium Ra 223 dichloride 4pembrolizumab 4luprolide acetate gel depot 4cabozantinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Clinical Trials, Phase I as Topic × 30 days × Clear all
NCT01171898 2026-05-11

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Aragon Pharmaceuticals, Inc.

Phase 1/2 Completed
127 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡